Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arvinas
Biotech
Pfizer, Arvinas' PROTAC posts mixed results in first ph. 3 test
Vepdegestrant was unable to show an improvement in PFS in the intent-to-treat population.
James Waldron
Mar 11, 2025 10:06am
Marea, Ashibio, Arvinas & more—Chutes & Ladders
Jun 21, 2024 8:30am
Xaira, Anthos, CureVac & more—Chutes & Ladders
Apr 26, 2024 8:30am
Novartis pays $150M for Arvinas' prostate tumor protein degrader
Apr 11, 2024 8:04am
Bayer undergoes leadership shake-up—Chutes & Ladders
Mar 22, 2024 9:30am
Arvinas advances anti-resistance cancer drug on sign of efficacy
Jun 8, 2023 9:30am